Moldotashev I K
Ter Arkh. 1988;60(2):92-6.
A study was made of the peculiarities of therapy of chronic heart failure (CHF) resulting from rheumatic heart disease under low-altitude (200 patients) and high-altitude (139 patients) conditions using strophanthin (76 patients), digoxin (76 patients), myofedrin (30 patients), nitroglycerin (43 patients), nitrong (35 patients), corvaton (46 patients), hydralazine (40 patients), nifedipine (52 patients), and verapamil (31 patients). It was shown that glycoside intoxication was twice as frequent in the patients with severe CHF under high-altitude conditions requiring the use of lower doses of cardiac glycosides and more thorough medical control. Better response to nitrates, corvaton, hydralazine, and nifedipine in multimodality treatment of CHF was found in mountain dwellers. Low clinical and hemodynamic results and frequent side effects of myofedrin and verapamil were established limiting their wide use in CHF patients living under high-altitude conditions.
对200例低海拔地区和139例高海拔地区风湿性心脏病所致慢性心力衰竭（CHF）患者使用毒毛花苷（76例）、地高辛（76例）、米力农（30例）、硝酸甘油（43例）、硝普钠（35例）、卡维他（46例）、肼屈嗪（40例）、硝苯地平（52例）和维拉帕米（31例）进行治疗特点的研究。结果表明，在高海拔条件下重度CHF患者中，洋地黄中毒发生率是低海拔地区的两倍，这就需要使用更低剂量的强心苷并进行更严格的医疗监控。在多模式治疗CHF中，山区居民对硝酸盐、卡维他、肼屈嗪和硝苯地平的反应更好。已证实米力农和维拉帕米临床和血流动力学效果不佳且副作用频繁，限制了它们在高海拔地区CHF患者中的广泛应用。
